Exopolysaccharides from Klebsiella oxytoca: anti-inflammatory activity by Thays Avelino Bannwart (13639494)

“…Gas chromatography-mass spectrometry analyses demonstrated that the EPS consisted of rhamnose (29.83%), glucose (11.21%), galactose (52.45%), and mannose (6.50%). The treatment of an experimental pleurisy model in rats through subcutaneous administration of 50, 100, 200, and 400 mg/kg of KEPS decreased both the volume of inflammatory exudate and the number of leukocytes recruited to the pleural cavity. …”

Table 1_Tofacitinib as an adjuvant treatment for pediatric Still's disease.docx by Ling Hou (42622)

“…The other nine patients received tocilizumab and had a decreased frequency of these injections after tofacitinib initiation. …”

Mechanical and microstructure characterization of hard nanostructured N-bearing thin coating by Cabibbo, M.

“…The main problem with steel, is that it exhibits a relatively low hardness (below 10GPa) which strongly decreases upon annealing above about 600K. …”
Get full text

Difference and Equilibrium spectra and modelling of the putative R and M absorption spectra. by Ludovic S. Mure (262696)

“…Consistent with typical difference spectra of invertebrates, the response function (5-degree polynomial, R² = 0.91) shows two domains: a decrease in the response between 400–515 nm (min = 466 nm) and an increase in constriction for longer wavelengths (515–650 nm, max = 592 nm). …”

Table_1_Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.docx by Xinqing Lin (9659243)

“…Background<p>Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). …”

Image_6_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

DataSheet_1_Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.xlsx by Xinqing Lin (9659243)

“…Background<p>Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). …”

Table_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.doc by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_3_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Data_Sheet_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.docx by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_4_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_2_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Lin28 increased the mammosphere formation rate and ALDH1 activity in breast cancer cells. by Yujie Liu (188278)

Thirty-year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes by Michael Fang (9708234)

“…</p> <p><b>Results: </b>From 1988-1994 to 2011-2018, there was a significant decrease in the prevalence of albuminuria (38.9 to 18.7%, p-for-trend<0.001), but no change in the prevalence of reduced eGFR (7.5 to 9.9%, p-for-trend=0.30), retinopathy (1988-1994 to 1999-2008 only; 13.2 to 12.1%, p-for-trend=0.86), or self-reported cardiovascular disease (19.0 to 16.5%, p-for-trend=0.64). …”

Expression of Sox2, Sox10, Gata3, Prox1 and Peripherin during primary auditory neuron development and maturation. by Koji Nishimura (2077804)

“…At E10.5, Sox10 was downregulated as neuroblasts delaminated from the otocyst. …”

Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes: Supplementary materials by William L Herring (14039541)

“…The fibrosis worsening profile reduced predicted 10-year LRC rates (F1:</p> <p>1.9%; F2: 6.5%; F3: 19.1%; F4/CC: 55.0%) more than the resolution and fibrosis improvement profiles</p> <p>(F1: 2.6%/2.6%; F2: 8.5%/8.3%; F3: 23.3%/23.0%; F4/CC: NA/59.0%). …”

Secondary metabolites from <i>Gentiana cruciata</i> L. and their anti-inflammatory and analgesic activities by Rima Konya (14075753)

“…<p>A previously unreported secoiridoid glycoside, cruciatoside (<b>1</b>) was isolated from the aerial parts of <i>Gentiana cruciata</i> L. along with ten known compounds eustomoside (<b>2</b>), eustomorusside (<b>3</b>), gentiopicroside (<b>4</b>), 6'-<i>O</i>-β-D-glucopyranosyl gentiopicroside (<b>5</b>), loganic acid (<b>6</b>), isoorientin (<b>7</b>), isovitexin (<b>8</b>), isovitexin 2''<i>-(E)-</i>ferulate (<b>9</b>), mangiferin (<b>10</b>), and 2-methyl-inositol (<b>11</b>). …”

MPs^PPARα+/+-induced EPC differentiation and <i>in vitro</i> angiogenesis of mature ECs involve NF-κB pathway activation. by Tarek Benameur (196206)

“…<p>(<b>A</b>) Western blot showing that MPs^PPARα+/+ induced I-κB phosphorylation on activator sites (Ser32/36) in EPCs, indicating that NF-κB pathway is activated. …”

DNMT1-mediated demethylation of lncRNA MEG3 promoter suppressed breast cancer progression by repressing Notch1 signaling pathway by Tingting Pan (4735617)

“…Functionally, treatment of breast cancer cells with the DNA methylation inhibitor 5-AzadC as well as silencing of DNA methyltransferase-1 (DNMT1) could decrease the abnormal hypermethylation of the MEG3 promoter, reverse MEG3 expression, inhibit cell proliferation and promote cell apoptosis. …”